ESPERION THERAPEUTICS INC (ESPR)

Company Profile

Esperion Therapeutics, Inc. is a pharmaceutical company. The company is headquartered in Vero Beach, Florida and currently employs 199 full-time employees. The company went IPO on 2013-06-24. The firm is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). The firm's bempedoic acid and the bempedoic acid / ezetimibe combination tablets are oral, once-daily, non-statin, LDL-C lowering medicines for patients with atherosclerotic cardiovascular disease (ASCVD), or heterozygous familial hypercholesterolemia (HeFH). The firm's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NEXLIZET and NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.

Company Info

ESPERION THERAPEUTICS INC

601 21St Street, Suite 300

Vero Beach FLORIDA 48108

P: 17724532770

CEO: Tim M. Mayleben

Employees: 199

Website: https://www.esperion.com/